12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Neratinib oral: Interim Phase I data

Interim data from 10 evaluable patients in an open-label, dose-escalation, U.S. Phase I trial showed that once-daily oral 120, 160 and 240 mg doses of neratinib plus trastuzumab and paclitaxel produced 1 complete response, 3 partial responses and 1 case of stable disease. DLTs included grade 3 diarrhea with dehydration at the 120...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >